Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced its plan to implement full circulation of its H shares, converting domestic and unlisted foreign shares into H shares, pending regulatory approvals. This move aims to enhance the company’s share capital structure and market presence, with proposed amendments to its Articles of Association reflecting these changes.
The most recent analyst rating on (HK:6990) stock is a Hold with a HK$434.36 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on developing and manufacturing biopharmaceutical products, with a market presence in Hong Kong.
Average Trading Volume: 817,589
Technical Sentiment Signal: Buy
Current Market Cap: HK$119.3B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.